Inmune Bio, INC 8-K filings

INmune Bio Inc. will host a conference call on August 1, 2024, to discuss its second quarter 2024 financial results and provide a corporate update.

INmune Bio Inc. held its annual meeting of stockholders on July 19, 2024, where directors were elected and the appointment of an independent auditor was ratified.

INmune Bio Inc. reports the immediate resignation of director Edgardo Baracchini, effective July 5, 2024.

INmune Bio's Phase II Alzheimer's trial, AD02, is confirmed to be appropriately powered following a blinded interim analysis of the primary endpoint, EMACC.

INmune Bio's CEO, Raymond J. Tesi, was granted an option to purchase 37,882 shares of the company's common stock at an exercise price of $8.72.

INmune Bio Inc. will be included in the Russell 3000 Index effective July 1, 2024, which is expected to increase the company's visibility and broaden its shareholder base.

INmune Bio Inc.'s Board of Directors has approved an amendment to the company's bylaws, changing the voting standard for the election of directors from a plurality to a majority vote, effective May 22, 2024.

INmune Bio's Board of Directors approved the issuance of stock options to non-employee directors and key executives, including the CEO, CFO, and CSO.

INmune Bio announced its first quarter 2024 financial results, provided a business update, and disclosed the successful raising of $14.5 million in equity capital.

INmune Bio announces the completion of the first cohort and initiation of the second cohort in its Phase 1/2 trial of INKmune for prostate cancer, and provides an update on two Alzheimer's patients receiving XPro under compassionate use for over three years.

INmune Bio, a clinical-stage immunology company, has successfully raised approximately $9.7 million through a registered direct offering of common stock and warrants.

INmune Bio announces successful completion of 24-month stability validation for XPro and files a patent application for a novel anti-drug antibody assay.

INmune Bio, a clinical-stage immunology company, has raised approximately $4.8 million through a registered direct offering of common stock and warrants, with company insiders purchasing about 20% of the offering.

INmune Bio is presenting data at AACR 2024 showing that INB03, a soluble TNF inhibitor, demonstrates potential in treating high-risk breast cancer by modulating immune checkpoints and reducing metastasis.

INmune Bio reported a net loss of $30 million for 2023, while also providing updates on their clinical programs and upcoming milestones.

INmune Bio Inc. will host a conference call on March 28, 2024, to discuss its fourth quarter 2023 financial results and provide a corporate update.

INmune Bio's Phase II clinical trial for Alzheimer's disease is back on track after the FDA lifted a clinical hold, with enrollment expected to complete mid-2024 and top-line data anticipated six months later.